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Abstract. Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that
mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas
other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs,
studies on their biotransformations and pharmacokinetics would facilitate the understanding and
prevention of unwanted drug–drug interactions (DDIs). A stable, principal metabolite of an IAA drug
of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the
metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and β-
carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6)
in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations
in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status,
and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs.
Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic
levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential
DDIs of these therapeutic and abused IAA drugs are described.
KEYWORDS: CYP2D6; drug interactions; indolealkylamine; metabolism; MAO; pharmacogenetics;
tryptamine.
INTRODUCTION
Indolealkylamines (IAAs) are chemical derivatives of 5-
hydroxytryptamine (5-HT or serotonin), a monoamine neu-
rotransmitter that modulates human mood and behaviors.
Structurally, these compounds all possess an indole moiety
and a basic nitrogen atom, which are connected by an alkyl
chain usually of two carbons in length. Acting on the
serotonergic system, some IAA agents such as ergotamine and
triptan drugs (e.g. sumatriptan, naratriptan and almotriptan)
(Fig. 1) have been successfully developed for antimigraine
therapy (1–3).
Many other IAA agents are important as widely abused
substances although some show potential in psychopharmaco-
therapy. This group of IAA agentsconsistsof lysergic acid amides
such as D-lysergic acid diethylamide (LSD) and ergine (LSA),
tryptamines such as psilocybin, N,N-dimethyltryptamine
(DMT), bufotenine, 5-methoxy-N,N-dimethyltryptamine (5-
MeO-DMT) and 5-methoxy-N,N-diisopropyltryptamine (5-
MeO-DIPT), and β-carbolines such as harman, harmaline and
harmine (4–6)( F i g .2). Tryptamine (e.g. 5-MeO-DMT) and β-
carboline (e.g. harmaline) derivatives are sometimes abused
together. These substances are readily synthesized in under-
ground laboratories, sold via the internet and abused particu-
larly by teenagers and young adults. As an unscheduled
substance, 5-MeO-DMT has even been referred to as the next
generation designer drug to replace “ecstasy.” Cases of IAA
intoxication have been continuously documented in the United
States (7–9). Overdosing or combined abuse of IAA agents may
cause severe or even fatal hyperserotonergic toxicity, namely
“serotonin syndrome” (10,11). Of note, serotonin toxicity has
become an important clinical problem over the last 15 years with
the increasing use of psychotropic agents.
A substantial body of research has revealed considerable
variations in the metabolic and pharmacokinetic properties
for therapeutic triptan agents, and provided adequate data to
predict metabolic drug–drug interactions (DDIs) in clinical
practice. In contrast, the metabolism of IAA drugs of abuse
has not been fully characterized because of legal, ethical and
safety issues associated in conducting human tests. For these
agents, a stable metabolite, measured by a reliable analytical
method, may serve as a better approach for forensic analysis.
Many metabolic data were therefore obtained from animal
studies, in which the discrepancy is obvious for some drugs
(12,13). Furthermore, the specific role of individual drug-
metabolizing enzymes including monoamine oxidases (MAO)
and cytochrome P450 (P450 or CYP) enzymes (14) remains
undefined, and mechanistic understanding of potential DDIs
with other abused or therapeutic agents is mostly unknown.
Increased knowledge in this area may advance our under-
standing of individual vulnerability to and/or protection from
illicit drugs of abuse (15). This review, therefore, aims to
describe our current understanding of the metabolism and
potential DDIs of IAA drugs.
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buffalo.edu)METABOLISM AND DRUG–DRUG INTERACTIONS
OF THERAPEUTIC INDOLEALKYLAMINE DRUGS
Mechanisms of Indolealkylamine Drugs for Antimigraine
Therapy
Ergotamine remains as a useful drug for acute treatment
of severe migraine attacks (1,16). It is an ergot alkaloid
originally isolated from fungus, and its pharmacological
property in relieving migraine headache was shown about
70 years ago. Its antimigraine effect is generally attributed to
the actions on 5-HT1B/1D receptors, whereas its side effects
may be caused by the nonselective actions on a variety of
other receptors including dopamine and 5-HT1A receptors.
In contrast to the complex mode of actions of ergota-
mine, newer IAA antimigraine drugs, namely triptans, are
much more selective for 5-HT1B and 5-HT1D receptors with
high affinity (2,3). Sumatriptan is the first of these “new
generation” IAA antimigraine agents that are better tolerated
by patients. The pharmacokinetics properties of these triptans
are quite diverse. For instance, the oral bioavailability of
sumatriptan is about 14% whereas naratriptan is 63–74%. The
elimination half-life of sumatriptan is 2 h whereas for
frovatriptan, it is 25 h (Table I). The sharp difference in
elimination of different triptans is at least partly due to the
marked difference in the metabolism of these drugs.
Metabolism and Drug–Drug Interactions of Ergotamine
and Triptans
Although ergotamine is known to be extensively metabo-
lized in the liver, its metabolicpathways are largely undefined in
humans. Nonetheless, there is good evidence from animal
studies supporting that CYP3As are the major enzymes
responsible for ergotamine metabolism (17). Indeed, CYP3A
inhibitory drugs such as erythromycin and troleandomycin are
known to decrease ergotamine metabolism and may lead to
unwanted DDIs. To prevent such metabolic DDIs and
potentially adverse drug effects, concomitant use of ergotamine
with CYP3A4 inhibitory drugs should be avoided.
Deamination metabolism is the predominant pathway for
sumatriptan (18) and rizatriptan (19), and a major route for
almotriptan (20). MAO-A is the principal enzyme responsible
for initiating the biotransformation (Table I). Their end
metabolites, indole acetic acids, are inactive and can be
readily recovered in urine. For instance, 50% of orally
administered and 35% of intravenously administered (14)C-
rizatriptan was excreted as triazolomethyl-indole acetic acid
in human urine (19). As expected, concurrent administration
of MAO-A inhibitors such as moclobemide may decrease the
clearance of these triptans and increase the systemic exposure
(20).
The other major pathway for almotriptan metabolism is
hydroxylation, which is catalyzed mainly by CYP3A4 and
CYP2D6 (20). In addition to deamination inactivation,
rizatriptan undergoes N-oxygenation, 6-hydroxylation and
N-demethylation (19). The N-monodesmethyl-rizatriptan,
formed to a minor degree, exhibits similar pharmacological
activity as the parent drug at the 5-HT1B/1D receptors. In
contrast, 6-hydroxy-rizatriptan and the N-oxide produced by
phase I drug-metabolizing enzymes are not active at the 5-
HT1B/1D receptors.
N-Demethylation is the main metabolic pathway for
zolmitriptan (Fig. 3), eletriptan and frovatriptan. CYP1A2 is
the major enzyme mediating N-demethylation of zolmitriptan
(21) and frovatriptan (22,23), and CYP3A4 is the primary
enzyme catalyzing N-demethylation of eletriptan (24). In vitro
studies have also revealed that CYP3A4 inhibitors can
significantly reduce eletriptan N-demethylation (22,23). Be-
cause zolmitriptan is primarily excreted via this oxidative
metabolic route, CYP1A2 inhibitors and inducers are
expected to significantly alter the clearance and systemic
exposure of zolmitriptan (21). In contrast, the CYP1A2
inhibitor fluvoxamine has been shown to have minor effects
onfrovatriptanpharmacokinetics,primarilybecausefrovatriptan
is significantly eliminated by renal clearance (22).
In contrast to the inactive N-desmethyl-frovatriptan, the
N-demethylated metabolites from zolmitriptan and eletriptan
are both active at the 5-HT1B/1D sites. In particular, the N-
desmethyl-zolmitriptan acts on 5-HT1B/1D receptors with an
affinity about two- to six-fold of that of zolmitriptan and its
steady state concentration is also higher than the parent drug.
Therefore, N-desmethyl-zolmitriptan may have important
contribution to the overall zolmitriptan drug effects. This
Fig. 1. Chemical structures of the 5-HT neurotransmitter and some
antimigraine triptan drugs
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deamination metabolism, resulting in an inactive indole
acetic acid derivative (21)( F i g .3). Because zolmitriptan is
extensively N-demethylated and N-desmethyl-zolmitriptan
is primarily excreted via deamination, potent MAO-A
inhibitors are anticipated to alter the pharmacokinetics of
N-desmethyl-zolmitriptan in humans. Indeed, concurrent
use of selective MAO-A inhibitor, moclobemide, has been
shown to cause 1.5- to 3-fold increase in the systemic
exposure (AUC) and peak drug concentration (Cmax) of
N-desmethyl-zolmitriptan (25).
Additionally, some N-demethylated triptan metabolites
may be further hydroxylated or N-acetylated (e.g. frovatriptan),
and a small portion of the parent triptans may be converted to N-
oxide (e.g. zolmitriptan by CYP1A2; Fig. 3). These information
may aid our understanding of the pharmacokinetics of triptans
and in predicting their unwanted metabolic DDIs.
METABOLISM AND DRUG–DRUG INTERACTIONS
OF INDOLEALKYLAMINE DRUGS OF ABUSE
Widespread Abuse of Indolealkylamine Drugs
Since the discovery of hallucinogenic properties for LSD
(Fig. 2), which include the alteration and distortion of human
perceptions, this agent has been used by millions of people in
the United States and elsewhere for quasi-religious and
recreational purposes. Other psychedelic IAA drugs of abuse
include psilocybin, DMT, bufotenine, 5-MeO-DMT, 5-
MeODIPT, harman, harmine, harmaline and ibogaine
(Fig. 2) that are all 5-HT analogs.
Many IAAs have been found to be the psychoactive
ingredients of a wide range of plant, fungus and animal
preparations, which have been used in social and religious
cultures in history. 5-MeO-DMT and bufotenine are the
Table I. Comparative Overview of the Metabolic and Pharmacokinetic Data of Triptan Drugs
Triptan drug Oral bioavailability (%) T1/2 (h) Major metabolic pathway Dominant enzyme Active metabolite
Sumatriptan ~14 ~2 Deamination MAO-A No
Zolmitriptan ~40 ~3 N-Demethylation CYP1A2 Yes
Naratriptan 74 (female), 63 (male) ~6 Not reported P450s No
Rizatriptan ~47 2–2.5 Deamination MAO-A No
N-demethylation P450s Yes
Eletriptan ~50 4–5 N-Demethylation CYP3A4 Yes
Almotriptan ~70 ~3.6 Deamination MAO-A No
Hydroxylation CYP3A4/2D6
Frovatriptan 30 (female), 24 (male) ~25 N-Demethylation and hydroxylation CYP1A2 No
Fig. 2. Chemical structures of some indolealkylamine drugs of abuse that consist of D-lysergic acid amides (e.g.
LSD and LSA), tryptamine derivatives (e.g. psilocybin, DMT, bufotenine, 5-MeO-DMTand 5-MeO-DIPT), β-
carbolines (e.g. harman, harmaline and harmine) and ibogaine
244 Yumajor ingredients of the venom of psychoactive toads such as
Colorado River Bufo alvarius (26,27). 5-MeO-DMT is also
the psychoactive agent in numerous plant preparations
including Virola snuffs. Harmaline, harmine, tetrahydrohar-
mine and DMT are important active constituents of the
beverage Ayahuasca (28). Several methylated IAAs have been
detected as endogenous compounds in humans. 5-MeO-DMT
can be synthesized in human pineal gland and has been
detected in both pineal gland and urine (29–31). The methyl-
ated IAAs are also present in retina at relatively high levels
(32). Derived from 5-HT through methylation (methylated
IAAs) and Pictet–Spengler condensation (β-carbolines), the
presence of these psychedelic IAAs in humans is certainly clear.
Although their biological roles and association with psychiatric
diseases are still obscure, increased understanding of their
metabolic pathways (33,34) would be helpful in answering these
questions.
Presently, IAA drugs are readily synthesized in clandes-
tine laboratories and sold via the internet. Studies by
Monitoring the Future programs (35) have revealed that, in
every year since 1991 to 2006, more than 8.3% of 12th-
graders have used hallucinogens. The abuse of hallucinogenic
substance other than LSD remains over 8.0% since 2001.
Additionally, nearly 50% of teenagers surveyed since 2001
said that it was “fairly easy” or “very easy” to get
hallucinogens other than LSD. As a presently unscheduled
hallucinogen, 5-MeO-DMT has been suggested as the next
generation designer drug to replace “ecstasy” and it is often
used in combination with harmaline (also an unscheduled
substance in the USA). Intoxications due to IAA drugs have
been frequently reported in hospitals in recent years (7–9).
These psychoactive IAA agents have also shown some
therapeutic value in treating mental health disorders. For
instance, ayahuasca may be utilized for the treatment of
alcoholism, serotonergic defects and substance abuse (28),
and ibogaine for cocaine addiction (36). Indeed, IAAs act on
a variety of 5-HT receptors, serotonin transporter, or MAO
enzyme that are highly favorable molecular targets for
treating depression, anxiety, schizophrenia, and other psychi-
atric disturbances (37). Nevertheless, medical use of these
agents remains a challenge because IAA drug responses
exhibit considerable variability in humans (38), and concerns
about their safety and abuse liability persist (28,39).
Mechanisms of Action of Indolealkylamine Drugs of Abuse
LSD was thought initially to act through 5-HT antago-
nism in the central nervous system or through mimicry of 5-
HT actions by interacting with the 5-HT receptor. After 5-HT
was firmly established as a neurotransmitter, it was found that
LSD inhibited the activity of serotonergic neurons. With the
delineation of 5-HT receptor subtypes and the extension of
serotonergic actions to other hallucinogenic agents, Glennon
et al. (40) established an excellent correlation between the
hallucinogenic potency and the affinity of IAAs for 5-HT2
receptors. Collective evidence from biochemical, physiologi-
cal and behavioral tests suggests that these hallucinogens
likely act on a common site of 5-HT2A and other 5-HT2
receptors in the central nervous system (5).
The pharmacological and toxicological effects of 5-
MeO-DMT, however, were believed to act through the 5-
HT1A receptor, as supported by results summarized by Winter
et al. (41). Furthermore, the inhibition of MAO enzyme or 5-HT
uptake was thought to be important for the actions of β-
carbolines such as harmaline in its induction of hypothermia
(42,43). The hallucinogenic effects of harmaline are likely
produced from binding to 5-HT2A and 5-HT2C receptors, and
the tremorgenic properties are due to the interactions with
benzodiazepine receptors (44–46). Because harmaline stimulates
locus coeruleus neuronal activity, it was even proposed as an
endogenous ligand for imidazoline receptors (47).
Fig. 3. Biotransformation of an antimigraine triptan drug, zolmitriptan. CYP1A2, cytochrome P450 1A2; MAO-A,
monoamine oxidase A; ALDH, aldehyde dehydrogenase
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characteristics for IAA intoxication in humans (26). Distorted
perception of time or auditory effects may also occur. In
animals, IAA drugs (e.g. harmaline that is discussed above)
are known to cause a variety of drug effects including
physiological (e.g. body temperature), biochemical (e.g.
monoamine neurotransmitters), and behavioral (e.g. discrim-
inative control) changes. Despite some exceptions (48), there
is a strong correlation between the discriminative stimulus
effects in non-verbal species and subjective effects in humans
(49–51).
There are significant variations of drug effects for
individual IAA agents in humans (4,26–28,38). Some individ-
uals can be adversely affected by IAA drugs including LSD,
5-MeO-DMT, bufotenine, and harmaline, some may not have
any response, and yet others would use them with impunity.
Meanwhile, depending upon the doses, 5-MeO-DMT may
induce hypothermic or hyperthermic effects in animals
(52,53). Unfortunately, a clear understanding of the molecu-
lar basis and the vulnerability to IAA substances is still
lacking.
Metabolism of Indolealkylamine Drugs of Abuse
Metabolism of D-Lysergic Acid Diethylamide
LSD is extensively metabolized in laboratory animals
and only a trivial fraction of the parent drug is excreted in
urine. Major metabolites of LSD detected in the rat and
guinea pig urines were the 13- and 14-hydroxy-LSD (HO-
LSD) and their corresponding glucuronic acid conjugates
(54). Other metabolites included 2-oxo-LSD, lysergic acid
ethylamide (LSE) and N-desmethyl-LSD (nor-LSD). In the
isolated perfused rat liver, aromatic hydroxylation was shown
as the principal metabolic pathway (55). However, studies on
LSD metabolism in rat liver microsomes indicated that nor-
LSD and LSE were the major metabolites, followed by 13-
hydroxy-LSD (56). The metabolism of LSD was more
complex in rhesus monkey because the urine consisted of at
least nine metabolites. In contrast to the metabolism in rats
and guinea pigs, aromatic hydroxylation was a minor
metabolic pathway in rhesus monkey (54). Thus, significant
difference in LSD metabolism between humans and labora-
tory animals has been observed.
Indeed, at least four metabolites have been identified in
urine from human users of LSD, which include 2-oxo-3-
hydroxy-LSD (2-oxo-3-HO-LSD), nor-LSD, 13- and 14-
hydroxy-LSD glucuronides (57) (Fig. 4). Although other
metabolites such as LSE were produced as major metabolites
from LSD incubated with human liver microsomes (58), 2-
oxo-3-HO-LSD was shown to be the main human urinary
metabolite, which may be present at 4- to 41-times higher
concentration than urinary LSD (59). This metabolite there-
fore holds promise as a biomarker for LSD use in the forensic
toxicology laboratories.
The detection of 2-oxo-LSD in human body fluids
indicates that 2-oxo-3-HO-LSD may be formed in two steps
via the 2-oxo-LSD intermediate. Recent studies on LSD
metabolism in human liver microsomes and hepatocytes not
only confirmed the formation of 2-oxo-3-HO-LSD but also
identified a 2,3-dihydroxy-LSD metabolite (60). This finding
suggests that 2-oxo-3-HO-LSD could be produced through
dehydrogenation of the 2,3-dihydroxy-LSD intermediate,
which is presumably formed from LSD 2,3-epoxide.
Fig. 4. Metabolism of LSD. Note that the 2-oxo-3-hydroxy-LSD (2-oxo-3-HO-LSD) has been shown as a
principal metabolite in the LSD-positive human urine samples
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further well-controlled studies are warranted to validate
whether 2-oxo-3-HO-LSD is indeed the major metabolite
(59) and to delineate the particular mechanisms that are
involved in the formation of this metabolite (60). Further-
more, almost nothing is known regarding the contribution of
specific drug-metabolizing enzyme to the production of
individual LSD metabolites in humans. Advance in these
areas could facilitate forensic detection, as well as the
prediction and prevention of potential metabolic DDIs
between LSD and other substances.
Metabolism of Tryptamine Derivatives
Like tryptamine itself (31,61), tryptamine derivatives
including DMT, bufotenine and 5-MeO-DMT are excreted
primarily via oxidative deamination and a predominant role for
MAO-A is certain in this metabolic pathway (62–66). How-
ever, there are some discrepancies among animal studies
reported in the literature. Sitaram’s group (13,67,68)s h o w e d
that DMT and 5-MeO-DMT were metabolized through
deamination, N-demethylation, O-demethylation, and N-oxy-
genation, and found that N-oxides were the major metabolites
in rat tissues. In contrast, oxidative deamination and O-
demethylation (followed by glucuronidation or deamination)
were shown to be the major pathways for (14)C-labeled 5-
MeO-DMT in rats (12). Our in vitro studies using human liver
microsomes, hepatocytes and recombinant enzymes agreed
with the importance of deamination for 5-MeO-DMT metab-
olism, while 5-MeO-DMT was shown to be O-demethylated
primarily by CYP2D6 (33,69)( F i g .5), a P450 enzyme that has
enormous genetic variations and is well recognized for its
clinical importance (70).
5-MeO-DMT O-demethylation is potentially an activa-
tion process because the metabolite bufotenine is a biologi-
cally active agent. Although the psychedelic activity for
bufotenine has been questioned (4,26,71), the confusion
probably arises due to its poor lipid solubility. A variety of
biochemical studies (71,72) supported the hypothesis that
bufotenine was a potent ligand at the 5-HT2A receptor with
an affinity up to ten-fold higher than 5-MeO-DMT. Vogel and
Evans (73) estimated that bufotenine was about three times
more potent than 5-MeO-DMT within the brain. Other
studies also indicated that bufotenine was psychoactive in
humans, as summarized by Ott (26,27). It is interesting to
note that bufotenine (the metabolite) is currently listed as a
Schedule I controlled substance, whereas 5-MeO-DMT (its
parent compound) is not. On the other hand, bufotenine may
be converted to 5-MeO-DMT in vivo by methyltransferase
(Fig. 5).
5-MeO-DIPT is also an abused tryptamine derivative,
which contains N,N-diisopropyl groups, rather than the N,
N-dimethyl groups within 5-MeO-DMT. The metabolism of
5-MeODMT vs. 5-MeO-DIPT can be compared (74).
Analyses of urine samples collected from 5-MeO-DIPT
users (75–77) suggested that this drug was mainly excreted
via metabolism, in particular, O- and N-dealkylation and
deamination (Fig. 6). Because isotope-labeled 5-MeO-DIPT
was not used and 5-HO-indole acetic acid is intrinsically
present in human urine, it is unclear which pathway is the
predominant route. Nonetheless, extensive studies using
human liver microsomes and recombinant enzymes
(74,78,79) revealed that CYP2D6 was responsible for 5-
M e O - D I P TO - d e a l k y l a t i o n ,w h i l eC Y P 1 A 2 ,3 A 4 ,2 C 1 9
enzymes mediated its N-dealkylation. The critical role for
CYP2D6 in 5-MeO-DIPT O-dealkylation might provide a
reasonable explanation for the sharp difference in urinary 5-
hydroxy-N,N-diisopropyltryptamine (5-HO-DIPT) level
that was observed between Caucasian and Japanese drug
users (75,77), if that Caucasian 5-MeO-DIPT user were to
have deficient CYP2D6 activity and the Japanese user have
regular CYP2D6 activity. Furthermore, 5-MeO-DIPT was
mainly O-dealkylated in human liver microsomes, whereas
it was primarily N-dealkylated in rat liver microsomes
(78,79). The sharp species difference in region-selective
metabolism of 5-MeO-DIPT, which is not unusual in drug
metabolism (80), may add complexity in the extrapolation of
animal data to humans.
Fig. 5. Deamination of bufotenine and 5-MeO-DMT produces corresponding indole acetic acid derivatives. 5-MeO-DMT can be
biotransformed to bufotenine through O-demethylation catalyzed primarily by CYP2D6, whereas bufotenine may be methylated to form
5-MeO-DMT
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above, psilocybin and psilocin are 4-substituted IAA drugs
that have been found in many psychedelic mushrooms
worldwide. Psilocin was readily detected in the blood and
urine from human subjects taken psilocybin (81). The
dephosphorylation of psilocybin to produce psilocin
(Fig. 7) appears to be an activation process. Identification
of other metabolites including 4-hydroxyindole acetic acid
(4-HO-IAA) and 4-hydroxyindole acetaldehyde suggested
that psilocin underwent deamination oxidation. Additionally,
the 4-hydroxy group of psilocin may be conjugated to form an
O-glucuronide (Fig. 7). In spite of these information, limited
studies on the metabolism of psilocybin and psilocin have been
reported, and specific enzymes that catalyze the formation of
individual metabolites remain unknown.
Metabolism of β-Carbolines and Ibogaine
β-Carbolines were shown to be good substrates for N-
methyltransferase and the corresponding cation products
were highly neurotoxic (82,83). In contrast, hydroxylation
and O-demethylation of β-carboline alkaloids, followed by
Fig. 7. Biotransformations of psilocybin and psilocin. Psilocybin is dephosphorylated to produce psilocin that
undergoes deamination and glucuronidation
Fig. 6. Metabolism of 5-MeO-DIPT. The O-demethylation is primarily mediated by CYP2D6 and N-deisopropylation is catalyzed by CYP1A2,
2C8, 2C9, 2C19 and 3A4
248 Yuglucuronidation and sulfation, are expected to be detoxifica-
tion processes that may play an important role in protection
against brain damage.
The metabolism of harmine is relatively well understood,
which includes two major oxidative pathways, O-demethyla-
tion and 6-hydroxylation (Fig. 8). Hydroxylation could also
occur at the 3- or 4-position of harmine (84). Hydroxyl β-
carboline metabolites such as harmol are readily conjugated
through glucuronidation and sulfation. The formation of
harmol from harmine exhibited three- to four-fold higher
Vmax in phenobarbitone-induced mouse liver microsomes
(85). Our recent study revealed that harmine O-demethyla-
tion was catalyzed by human CYP2D6, 1A1, 1A2, 2C9 and
2C19 enzymes (86). Furthermore, we found that CYP2D6
was a major enzyme mediating the O-demethylation of
harmaline and pinoline (33,86), suggesting an important role
for CYP2D6 in O-demethylation of these β-carbolines,
although its role in their total clearance has not been
determined yet. Given the fact that defect of CYP2D6 can
significantly alter the pharmacokinetics of CYP2D6 substrate
drugs, distinct pharmacokinetics may occur for these β-
carbolines due to different CYP2D6 status. Indeed, a recent
study (87) disclosed that there were two phenotypes in
harmine pharmacokinetics, fast and slow metabolism, in
humans. Further investigation will determine whether this is
because of CYP2D6 polymorphism, and whether this would
be translated into significant difference in drug responses.
Little is known for many other β-carbolines regarding
the specific enzymes that contribute to their biotransforma-
tion, although some of them have been shown to undergo
Fig. 8. Metabolism of harmine. One major pathway is O-demethylation mediated by CYP2D6, 1A and 2C
enzymes, and the metabolite harmol is subject to glucuronidation and sulfation. Hydroxylated harmine
metabolites have also been identified, which occur at the 6- and 3- or 4-positions of harmine
Fig. 9. Serotonergic neurotransmission. Hyperserotonergic effects may be induced when a
tryptamine derivative (5-HT receptor agonist) and a β-carboline (monoamine oxidase
inhibitor) are used concurrently. In particular, the β-carboline can reduce the degradation
of 5-HT neurotransmitter and inhibit the metabolism of tryptamine derivative
249 Indolealkylamines: Biotransformations and Potential Interactionsaromatic hydroxylations. The depletion of harman in mouse
liver microsomes was enhanced about 4- and 11-fold when
pretreated with phenobarbitone and 3-methylcholanthrene,
respectively. The major metabolite was found to be 6-
hydroxyharman the formation of which was likely mediated
by P450 enzymes (88), but it is unclear which particular
isozyme is involved. Interestingly, species difference was also
shown in the metabolism of tetrahydroharman (1-methyl-
1,2,3,4-tetrahydro-β-carboline). In vitro and in vivo studies
demonstrated that tetrahydroharman was hydroxylated at the
5-, 6- and 7-positions in rats (89), whereas it was mainly
hydroxylated at the 6- and 7-positions in humans (90,91).
Furthermore, 6-hydroxytetrahydroharman was present in both
free and conjugated forms, and 7-hydroxytetrahydroharman
mainly exist as a conjugated form in the urine from humans
administered with deuterated tetraharman.
Ibogaine is an indole alkaloid initially isolated from a
rain forest shrub, Tabernanthe Iboga, which is native to
Africa. It is a schedule I substance in the United States while
its potential as a pharmacotherapeutic agent in treating
cocaine and opiate addictions has been explored recently
(36). Even in a Phase I trial containing a limited number of
human subjects, ibogaine exhibited considerable variability in
the pharmacokinetics of parent drug and its major metabolite,
noribogaine (92). CYP2D6 was subsequently identified as the
predominant enzyme that catalyzed the formation of noribo-
gaine from ibogaine (93). Furthermore, noribogaine is
pharmacologically active and has a similar pharmacodynamic
profile as the parent drug with higher affinities to the opioid
receptors and serotonin transporter. An important contribu-
tion of noribogaine to the overall ibogaine drug effects and
the involvement of CYP2D6 polymorphism would also add
complexity in the use of ibogaine.
Potential Drug–Drug Interactions of Indolealkylamine Drugs
of Abuse
DDIs occur at the pharmacokinetic level when one drug
(perpetrator) alters the absorption, distribution, metabolism
or excretion of another drug (victim) and at the pharmaco-
dynamic level when the perpetrator and victim drugs work on
the common targets (e.g. receptors) of action. Severe or fatal
adverse reactions could be induced when pharmacokinetic
and pharmacodynamic DDIs arise together additively. This
may be true for IAA drugs that are abused concomitantly, in
particular, through the use of a tryptamine derivative (e.g. 5-
MeO-DMT) and a β-carboline (e.g. harmaline). First, harma-
line itself possesses psychotropic activities, which not only
inhibits MAO-mediated 5-HT degradation but also acts
directly on 5-HT receptors (46). Concomitant use of such
MAO inhibitor and 5-HT agonist would potentiate seroto-
nergic neurotransmission (Fig. 9). Second, by inhibiting
MAO-A activity, harmaline is anticipated to reduce 5-MeO-
DMT metabolic disposition, leading to an increased and
prolonged exposure to 5-MeO-DMT. Additionally, the inhi-
bition of MAO-A activity may shunt 5-MeO-DMT deamina-
tion to O-demethylation and results in elevated levels of the
psychoactive metabolite bufotenine, the formation of which
will depend on CYP2D6 status. A contribution of both 5-
HT2A and 5-HT1A receptors to the overall 5-MeO-DMT
drug effects is possible, and increased levels of bufotenine
may even convert 5-MeO-DMT (5-HT1A) dominant effects
to bufotenine (5-HT2A agonist) dominant effects. Such
complex DDIs among IAA drugs and the involvement of
CYP2D6 pharmacogenetics could represent additional risk
factors in IAA abuse.
The dominant role of CYP2D6 in ibogaine O-demethylation
metabolism also suggests that ibogaine may be subject to
metabolic DDIs with CYP2D6 inhibitors (93). Of note, some
selective serotonin reuptake inhibitors (SSRIs) such as parox-
etine and fluoxetine are potent inhibitors of CYP2D6. These
SSRIs have been known to cause DDIs with other psychotropic
drugs metabolized by CYP2D6. Quinidine is another known
potent inhibitor of CYP2D6 with an inhibitory potency in the
nanomolar range. A single oral dose of 50 mg of quinidine
strikingly altered the metabolism and disposition of CYP2D6
substrate drugs including debrisoquine, dextromethorphan and
codeine (94–96). Similarly, the potential of metabolic DDIs is
increased (93) for ibogaine with CYP2D6 inhibitory medications
including SSRIs.
Nevertheless, quantitative prediction of DDIs with IAA
drugs of abuse is extremely difficult because the precise
contribution of specific drug-metabolizing enzyme to the
overall clearance of an IAA drug (e.g. 5-MeO-DMT) or even
the enzymes involved (e.g. LSD) remains unknown. Secondly,
other factors including drug transporters and/or the target
receptors or enzymes may be affected simultaneously by the
drugs. Thus, theoretical predictions of DDIs with IAA drugs
can be quite complex, and would require clinical verification.
CONCLUSION
Acting on the serotonergic system, IAA drugs represent
a major class of abused hallucinogens. Some IAA drugs
however show potential in psychopharmacotherapy and
others have been developed as antimigraine agents. Studies
on the metabolism of triptans provide useful information to
predict adverse metabolic DDIs in clinical practice. In
contrast, there are limited metabolic data for IAA drugs of
abuse. Increased knowledge in this area could provide better
understanding of the hazards of IAA drugs of abuse,
including the potential of metabolic variability and adverse
interactions with other abused or therapeutic drugs.
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